Last reviewed · How we verify

Placebo (for aflibercept)

Sanofi · Phase 3 active Small molecule

Placebo (for aflibercept) is a Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Comparison control in clinical trials for aflibercept.

Placebo does not have a known mechanism of action.

Placebo does not have a known mechanism of action. Used for Comparison control in clinical trials for aflibercept.

At a glance

Generic namePlacebo (for aflibercept)
SponsorSanofi
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action. It is used as a control in clinical trials to compare the efficacy of active treatments.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo (for aflibercept)

What is Placebo (for aflibercept)?

Placebo (for aflibercept) is a Small molecule drug developed by Sanofi, indicated for Comparison control in clinical trials for aflibercept.

How does Placebo (for aflibercept) work?

Placebo does not have a known mechanism of action.

What is Placebo (for aflibercept) used for?

Placebo (for aflibercept) is indicated for Comparison control in clinical trials for aflibercept.

Who makes Placebo (for aflibercept)?

Placebo (for aflibercept) is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What development phase is Placebo (for aflibercept) in?

Placebo (for aflibercept) is in Phase 3.

Related